Review anchor
MCF7
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
MCF7
CHEMBL387
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats MCF7 as ChEMBL target CHEMBL387. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL387
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why MCF7 matters
MCF7 is reviewed as MCF7; the current evidence base includes 186 approved drugs, 96653 compounds, and 18745 assays, with lead potency reaching pChEMBL 11.0.
Protein context
MCF7
MCF7
Review this target as MCF7.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 186 approved drugs, 96653 compounds, and 18745 assays for this target. The dominant activity type is IC50. CHEMBL135 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL135 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
186 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why MCF7 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
96653
Total Compounds
18745
Total Assays
186
Approved Drugs
IC50: 55104.0, KI: 2.0, EC50: 1935.0, KD: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL135
|
11.0 | EC50 | Approved |
|
|
No preferred name
CHEMBL358471
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL1836548
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL1627930
|
10.9 | EC50 | — |
|
|
No preferred name
CHEMBL123405
|
10.9 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
INAVOLISIB
CHEMBL4650215
|
2024 |
|
|
ELACESTRANT
CHEMBL4297509
|
2023 |
|
|
CAPIVASERTIB
CHEMBL2325741
|
2023 |
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
TIRBANIBULIN
CHEMBL571546
|
2020 |
|
|
LONAFARNIB
CHEMBL298734
|
2020 |
|
|
ALPELISIB
CHEMBL2396661
|
2019 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
COPANLISIB
CHEMBL3218576
|
2017 |
|
|
TIVOZANIB
CHEMBL1289494
|
2017 |
|
|
NIRAPARIB
CHEMBL1094636
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
PANOBINOSTAT
CHEMBL483254
|
2015 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
IDELALISIB
CHEMBL2216870
|
2014 |
|
|
BELINOSTAT
CHEMBL408513
|
2014 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
ROMIDEPSIN
CHEMBL343448
|
2009 |
|
|
LASOFOXIFENE
CHEMBL328190
|
2009 |
|
|
CARFILZOMIB
CHEMBL451887
|
2009 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
BAZEDOXIFENE
CHEMBL46740
|
2009 |
|
|
TEMSIROLIMUS
CHEMBL1201182
|
2007 |
|
|
LAPATINIB
CHEMBL554
|
2007 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
PEMETREXED
CHEMBL225072
|
2004 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
MYCOPHENOLIC ACID
CHEMBL866
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
|
|
FULVESTRANT
CHEMBL1358
|
2002 |
|
|
IMATINIB MESYLATE
CHEMBL1642
|
2001 |
|
|
ESTRIOL
CHEMBL193482
|
2000 |
|
|
EPIRUBICIN
CHEMBL417
|
1999 |
|
|
PIOGLITAZONE
CHEMBL595
|
1999 |
|
|
LETROZOLE
CHEMBL1444
|
1997 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
RALOXIFENE HYDROCHLORIDE
CHEMBL1116
|
1997 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
METFORMIN
CHEMBL1431
|
1995 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
TENIPOSIDE
CHEMBL452231
|
1992 |
Source Header